Matter Bio is a longevity-focused company dedicated to preserving genome integrity and addressing the information loss that occurs in our DNA as we age. The company identifies four critical stages in the genomic information loss continuum: recognizing the loss of information, restricting further damage, repairing integrated mutations, and removing excessively mutated cells. By assembling a team of experts, Matter Bio aims to develop innovative solutions that counteract the detrimental effects of mutations, structural variations, and epigenetic drift, which contribute to aging and related diseases.

The company employs several advanced technologies to achieve its mission. One notable innovation is Spellcheck Bio, which functions as a "spellchecker" for the genome, allowing for precise DNA editing by detecting somatic mutations before making corrections. Additionally, Loki Therapeutics utilizes a unique immune-AWAKE™ bacterial platform that enhances immune responses against solid tumors through engineered Listeria, which selectively targets tumor cells and recruits immune cells to the tumor microenvironment. Furthermore, Matter Bio's MutagenTech leverages single-cell sequencing techniques that are significantly more efficient and cost-effective than traditional methods, enabling rapid detection of point mutations and facilitating better genomic analysis. Together, these technologies represent a comprehensive approach to combating the biological challenges of aging and cancer.

United States

Matter Bio is a longevity holding company focused on preserving genome integrity

As we age, our genome is constantly being damaged by exogenous and endogenous sources.

 Occasionally errors are missed and incorporated into the DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss.
 
At Matter, we have assembled a world-class team of scientists and executives to help counter this critical information loss in the genome.

To achieve this, we are focusing on a number of assets that address key stages in the genomic information loss continuum.

Matter Bio

Company Details